person, and providing financial advice to state and local governments and foreign governments, pursuant to § 225.25(b)(4) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, July 21, 1995.

### Jennifer J. Johnson,

Deputy Secretary of the Board. [FR Doc. 95–18462 Filed 7–26–95; 8:45 am] BILLING CODE 6210–01–F

# Norwest Corporation and Wells Fargo & Company, et al.; Notice of Applications to Engage de novo in Permissible Nonbanking Activities

The companies listed in this notice have filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage de novo, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 10, 1995.

A. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. Norwest Corporation, Minneapolis, Minnesota, through its wholly-owned subsidiary, Norwest Ventures, Inc., Des Moines Iowa, and Wells Fargo & Company, San Francisco, California, through its wholly-owned subsidiary, Wells Fargo Ventures, Inc., San Francisco California, propose to form a joint venture, Towne Square Mortgage, San Diego, California (which will be owned 85 percent by Norwest and 15 percent by Wells Fargo), and engage de novo in the residential mortgage lending business, including activities such as prequalification, mortgage loan origination and processing and closing loans, pursuant to § 225.25(b)(1) of the Board's Regulation Y. The geographic scope for these activities is the State of California, primarily at locations of Wells Fargo's subsidiary bank, Wells Fargo Bank, N.A. Comments on this application also may be submitted to the Federal Reserve Bank of San Francisco (Kenneth R. Binning, Director, Bank Holding Company) 101 Market Street, San Francisco, California 94105.

2. Dacotah Banks, Inc., Aberdeen, South Dakota; to engage de novo in making and servicing loans, pursuant to § 225.25(b)(1) of the Board's Regulation Y. The geographic scope for this activity is South Dakota.

**B. Federal Reserve Bank of New York** (William L. Rutledge, Senior Vice President) 33 Liberty Street, New York, New York 10045:

1. Barclays Bank PLC, London, England, and Barclays PLC, London, England; to engage de novo through their subsidiary, Barclays De Zoete Wedd Securities, Inc., New York, New York, in providing securities brokerage services, related securities credit activities, and securities brokerage services in combination with investment advisory services, pursuant to § 225.25(b)(15)(i) and (ii) of the Board's Regulation Y; and providing investment or financial advice, pursuant to § 225.25(b)(4)(i) through (vi) of the Board's Regulation Y.

C. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. Crystal Valley Financial
Corporation, Middlebury, Indiana; to
engage through its subsidiary, Crystal
Valley Financial Corporation,
Middlebury, Indiana, in retaining its
investment in a community
development corporation (a qualified
low-income housing project as defined
in section 42(c)(2) of the Internal
Revenue Code), through its investment
in a limited liability company; and

investing in an additional community development corporation (a qualified low-income housing project as defined in section 42(c)(2) of the Internal Revenue Code), through an investment in a limited liability company, pursuant to § 225.25(b)(6) of the Board's Regulation Y.

2. Horizon Bancorp, Michigan City, Indiana; to engage de novo through its subsidiary, The Loan Store, Inc., Michigan City, Indiana, in acting as agent or broker for insurance directly related to extension of credit, under § 225.25(b)(8)(ii) of the Board's Regulation Y

## **D. Federal Reserve Bank of Kansas City** (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas

City, Missouri 64198:

1. Stuart Family Partnership, The Catherine Stuart Schmoker Family Partnership, The James Stuart, Jr. Family Partnership, The Scott Stuart Family Partnership and First Commerce Bancshares, all of Lincoln, Nebraska; to engage de novo through First Commerce Bancshares, Inc., Lincoln, Nebraska, in the business of making loans pursuant, to § 225.25(b)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, July 20, 1995.

#### Jennifer J. Johnson,

Deputy Secretary of the Board. [FR Doc. 95–18463 Filed 7–26–95; 8:45 am] BILLING CODE 6210–01–F

### GENERAL SERVICES ADMINISTRATION

### Performance Review Boards for Small Client Agencies Serviced by the General Services Administration, Names of Members

Sec. 4314(c) (1) through (5) of Title 5 U.S.C., requires each agency to establish, in accordance with regulations prescribed by the office of Personnel Management, one or more Performance Review Boards. The board shall review and evaluate the initial appraisal by the supervisor of a senior executive's performance, along with any recommendations to the appointing authority relative to the performance of the senior executive. The Performance Review Board also shall make recommendations as to whether the career executive should be recertified. conditionally recertified, or not recertified.

As provided under Section 601 of the Economy Act of 1932, amended 31 U.S.C. 1525, the General Service Administration through its Agency Liaison Division, provides various personnel management services to a number of diverse Presidential commissions, committees, boards and other agencies through reimbursable administrative support agreements. This notice is proceeded on behalf of the client agencies, and it supersedes all other notices in the **Federal Register** on this subject.

Because of their small size, a Performance Review Board register has been established in which SES members from the client agencies participate. The Board is composed of SES members from various agencies. From this register of names, the head of each client agency will appoint executives to a specific board to serve a particular client agency.

The members whose names appear on the Performance Review Board standing roster to sere client agencies are:

Administrative Conference of the U.S. Gary J. Edles, General Counsel Jeffrey S. Lubbers, Research Director

Barry M. Goldwater Scholarship and Excellence in Education Foundation Gerald J. Smith, Executive Secretary

Board of International Broadcasting

Richard McBride, Executive Director John A. Lindburg, General Counsel Patricia H. Schlueter, Director of Financial and Congressional Affairs Bria T. Conniff, Inspector General

Committee for Purchase From People Who Are Blind or Severely Disabled

Beverly L. Milkman, Executive Director

Defense Nuclear Facilities Safety Board

Kenneth M. Pusateri, General Manager Joseph R. Neubeiser, Deputy General Manager

Robert M. Anderson, General Counsel Richard A. Azzaro, Deputy General Counsel for Policy and Litigation

George W. Cunningham, General Engineer Joyce P. Davis, Chief, Health Physics Branch Wallace R. Kornack, Assistant Director for Engineering

Steven L. Krahn, Assistant Director for Weapon Programs

Lester A. Ettlinger, Assistant Director for Standards

Harry S Truman Scholarship Foundation Louis H. Blair, Executive Secretary

Japan-United States Friendship Commission

Office of Navajo and Hopi Indian Relocation Christopher J. Bavasi, Executive Director Michael J. McAlister, Deputy Executive Director

Artic Research Commission
Garrett W. Brass, Executive Director
National Mediation Board
Ronald M. Etters, General Counsel

Eric J. Gangloff, Executive Director

Dated: July 18, 1995.

#### Calvin R. Snowden,

Director.

[FR Doc. 95-18486 Filed 7-26-95; 8:45 am] BILLING CODE 6820-34-M

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

CDC Recommendations for Civilian Communities Near Chemical Weapons Depots: Guidelines for Medical Preparedness; Correction

A notice was published in the **Federal Register** on June 27, 1995 (60 FR 33308), entitled, "CDC Recommendations for Civilian Communities Near Chemical Weapons Depots: Guidelines for Medical Preparedness." This notice is corrected as follows:

On page 33309, first column, line 6 of the second paragraph, change "falls" to "fall"; and in the second column, line 9, under the heading: 1. Personal Protective Equipment (PPE), change "have" to "has" and in line 11, change "portable" to "powered." On page 33311, second column, line 8, under the heading: 5. Personal Protective Equipment (PPE), change "have" to "has."

Dated: July 21, 1995.

### Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-18433 Filed 7-26-95; 8:45 am] BILLING CODE 4163-18-P

### Food and Drug Administration

### **Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

**MEETING:** The following advisory committee meeting is announced:

# Subcommittee Meeting of the National Task Force on AIDS Drug Development on Drug Development Issues

Date, time, and place. September 13 and 14, 1995, 8:30 a.m., Gaithersburg Hilton Hotel, Grand Ballroom, 629 Perry Pkwy., Gaithersburg, MD. A limited number of overnight accommodations have been reserved at the Gaithersburg Hilton Hotel. Attendees requiring overnight accommodations may contact the hotel at 301–977–8900 and reference the task force. Interested persons are encouraged to register early because space is limited.

Type of meeting and contact person. Open subcommittee discussion, September 13, 1995, 8:30 a.m. to 11:45 a.m.; open public hearing, 11:45 a.m. to 12:15 p.m., unless public participation does not last that long; open subcommittee discussion, 12:15 p.m. to 4:45 p.m.; open subcommittee discussion, September 14, 1995, 8:30 a.m. to 11:45 a.m.; open public hearing, 11:45 a.m. to 12:15 p.m., unless public participation does not last that long; Nancy L. Stanisic, Office of AIDS and Special Health Issues (HF-12), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-0104, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301–443–0572 in the Washington, DC area), National Task Force on AIDS Drug Development, code 12602.

General functions of the task force. The task force shall identify any barriers and provide creative options for the rapid development and evaluation of treatments for human immunodeficiency virus (HIV) infection and its sequelae. It also advises on issues related to such barriers, and provides options for the elimination of these barriers.

*Open subcommittee discussion.* The subcommittee will review, discuss, and clarify issues concerning the